<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565835</url>
  </required_header>
  <id_info>
    <org_study_id>2017-8506</org_study_id>
    <nct_id>NCT03565835</nct_id>
  </id_info>
  <brief_title>Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer</brief_title>
  <official_title>Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to find out if patients with prostate cancer being treated with the&#xD;
      medications abiraterone and prednisone can discontinue hormone injections (examples include&#xD;
      leuprolide, goserelin, triptorelin and degarelix). Abiraterone and prednisone are pills used&#xD;
      to treat patients with prostate cancer. When abiraterone and prednisone are used, hormone&#xD;
      injections are usually continued to maintain a low testosterone level in the blood. This&#xD;
      study is being done to find out if testosterone in the blood will stay low while abiraterone&#xD;
      and prednisone are used without continued hormone injections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abiraterone inhibits the CYP17A enzyme, which is a critical enzyme in androgen biosynthesis.&#xD;
      Abiraterone has regulatory approval in metastatic castration-resistant prostate cancer&#xD;
      (mCRPC) in both chemotherapy-naïve and in the post-docetaxel setting based upon results from&#xD;
      two randomized phase III studies. Abiraterone is also proven to extend survival in the&#xD;
      metastatic, hormone-naïve population based on two phase III studies. Abiraterone is a&#xD;
      castrating agent, but, other than a small first in human study, all clinical studies have&#xD;
      been done in conjunction with gonadotropin-releasing hormone (GnRH) analogues. Maintaining&#xD;
      castrate level of serum testosterone is critical in the treatment of metastatic prostate&#xD;
      cancer. It is unknown if GnRH analogues must be continued to maintain castrate levels of&#xD;
      serum testosterone in patients treated with abiraterone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a non-castrate (&gt;50 ng/dl) serum testosterone</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess the proportion of patients with a non-castrate testosterone level (&gt;50 ng/dl) when abiraterone acetate plus prednisone is used without GnRH analogues in metastatic prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Luteinizing hormone (LH) level after discontinuation of GnRH analogue</measure>
    <time_frame>24 weeks</time_frame>
    <description>To measure serum LH level in patients with metastatic prostate cancer treated with abiraterone acetate plus prednisone without a GnRH analogue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>To measure PSA response rate and in patient with metastatic prostate cancer treated with abiraterone acetate plus prednisone without a GnRH analogue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>24 weeks</time_frame>
    <description>To measure the incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival (rPFS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>To measure the time for trial entry until radiographic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>To measure the median time from trial entry until death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Abiraterone and Prednisone without a GnRH Analogue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Abiraterone Acectate with Prednisone and with Discontinuation of GnRH Analogue</description>
    <arm_group_label>Abiraterone and Prednisone without a GnRH Analogue</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Abiraterone Acectate with Prednisone and with Discontinuation of GnRH Analogue</description>
    <arm_group_label>Abiraterone and Prednisone without a GnRH Analogue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be able to provide study-specific informed consent prior to study&#xD;
             entry&#xD;
&#xD;
          2. Age ≥ 18&#xD;
&#xD;
          3. ECOG Performance Status 0-2&#xD;
&#xD;
          4. Pathologically proven diagnosis of prostate adenocarcinoma&#xD;
&#xD;
          5. Patients must have metastatic prostate cancer&#xD;
&#xD;
          6. Patients may have mCRPC or may have metastatic castration-sensitive disease.&#xD;
&#xD;
          7. Patients must be maintained on a GnRH analogue (agonist (leuprolide, goserelin,&#xD;
             triptorelin, histerelin, deslorin) or antagonist (degarelix))&#xD;
&#xD;
          8. The patient and the investigator have decided that the next line of cancer therapy&#xD;
             will be abiraterone plus prednisone and the initial dose of abiraterone will be 1000&#xD;
             mg daily. Or patients may already be on abiraterone with prednisone at a dose of 1000&#xD;
             mg daily along with a GnRH analogue.&#xD;
&#xD;
          9. Lab values meeting the following criteria&#xD;
&#xD;
               1. Total testosterone level of &lt;50 ng/dl&#xD;
&#xD;
               2. Total bilirubin &lt; 2.0 X Upper Limit of Normal (ULN)&#xD;
&#xD;
               3. Aspartate aminotransferase (AST) ≤ 3 X ULN&#xD;
&#xD;
               4. Alanine aminotransferase (ALT ) ≤ 3 X ULN&#xD;
&#xD;
               5. Absolute Neutrophil Count &gt; 1.5 K/mm3&#xD;
&#xD;
               6. Platelets &gt; 100 K/mm3&#xD;
&#xD;
               7. Hemoglobin ≥9.0 g/dL&#xD;
&#xD;
               8. calculated creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         10. History of bilateral orchiectomy&#xD;
&#xD;
         11. History of hypopituitarism&#xD;
&#xD;
         12. For patient not yet started on abiraterone with prednisone, uncontrolled hypertension&#xD;
             (systolic blood pressure &gt;170 mm Hg or diastolic blood pressure &gt;100 mm Hg)&#xD;
&#xD;
         13. Patients must not have New York Heart Association Class III or IV heart failure at the&#xD;
             time of screening. Patients must not have any unstable angina, myocardial infarction,&#xD;
             or serious uncontrolled cardiac arrhythmia within 6 months prior to registration&#xD;
&#xD;
         14. Any other serious illness or medical condition that the principal investigator feels&#xD;
             would make the patient a poor candidate for this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Gartrell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>abiraterone</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

